Evolva’s resveratrol has been chosen to be used in an upcoming clinical trial at the University of Cincinnati on combination drug therapy for LAM (Lymphangioleiomyomatosis) patients. LAM is a cystic lung disease and is almost completely restricted to women. While lung cysts consistent with LAM are reported in some men with tuberous sclerosis, very few of these men develop symptoms. The prevalence of LAM is estimated using data from registries and patient groups and is between 3.4-7.8/million women.
Evolva’s resveratrol was chosen for this trial because of its innovative yeast fermentation production process. This closed system process results in a pure resveratrol that eliminates any possible impurities that would impact the health of the subjects or the results of the trial.
“Evolva has a history of supporting quality clinical research. We are pleased to be working with the University of Cincinnati in the search for treatment of patients with few options”, said Angela Tsetsis, SVP, Health and Wellness at Evolva. “We seek clinical opportunities where the purity of our Veri-teTM resveratrol provides unique benefits to improve health and wellness.”
To read the full Press Release from the University of Cincinnati Academic Health Center click HERE.